Healios KK (JP:4593)
:4593
Top Page
Healios KK
(4593)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥367.00
▲(0.00% Upside)
Action:ReiteratedDate:02/28/26
The score is held down primarily by weak financial performance—persistent large losses and worsening cash burn despite modest revenue growth and improved leverage. Technicals provide some offset with improving momentum above key moving averages, but valuation support is limited due to the negative P/E and no dividend yield.
Positive Factors
Focused regenerative medicine platform
A clear, specialized business model in cell therapy and regenerative medicine targeting ophthalmology and CNS provides durable strategic focus. Specialized R&D and external collaborations raise barriers to entry, support clinical progress, and create long-term commercialization pathways versus diversified peers.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow means the company consumes cash to fund operations and development. This elevates financing risk and the likelihood of dilutive capital raises, constraining strategic flexibility and potentially slowing clinical/commercial programs over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused regenerative medicine platform
A clear, specialized business model in cell therapy and regenerative medicine targeting ophthalmology and CNS provides durable strategic focus. Specialized R&D and external collaborations raise barriers to entry, support clinical progress, and create long-term commercialization pathways versus diversified peers.
Read all positive factors
Healios KK (4593) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥49.55B
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-82.33%
EPS Growth47.73%
CountryJP
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)18.90
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥965.00Price Target Upside162.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-42.73
Revenue Forecast (FY)¥658.52M
Healios KK Business Overview & Revenue Model
Company Description
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HL...
How the Company Makes Money
null...
Healios KK Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
41
Neutral
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 104.00M | 560.00M | 121.00M | 90.00M | 41.00M |
| Gross Profit | -389.00M | 432.00M | 108.00M | 90.00M | 41.00M |
| EBITDA | -3.13B | -2.54B | -3.16B | -4.52B | -3.61B |
| Net Income | -2.22B | -4.24B | -3.82B | -5.17B | -4.91B |
Balance Sheet | |||||
| Total Assets | 17.05B | 14.19B | 15.15B | 15.03B | 23.97B |
| Cash, Cash Equivalents and Short-Term Investments | 5.68B | 3.67B | 6.72B | 7.25B | 15.13B |
| Total Debt | 2.61B | 2.66B | 4.53B | 7.15B | 11.96B |
| Total Liabilities | 12.15B | 12.11B | 11.29B | 10.65B | 15.33B |
| Stockholders Equity | 4.89B | 2.06B | 3.86B | 4.38B | 8.64B |
Cash Flow | |||||
| Free Cash Flow | -3.33B | -1.83B | -2.85B | -4.86B | -5.39B |
| Operating Cash Flow | -3.17B | -1.82B | -2.82B | -4.60B | -5.09B |
| Investing Cash Flow | -1.11B | -1.42B | -1.12B | -909.00M | -736.00M |
| Financing Cash Flow | 6.33B | 77.00M | 3.34B | -2.50B | 6.99B |
Healios KK Technical Analysis
Negative
367.00
Price Trends
389.40
Negative
378.01
Negative
456.38
Negative
Market Momentum
-7.33
Positive
46.27
Neutral
38.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4593, the sentiment is Negative. The current price of 367 is below the 20-day moving average (MA) of 385.35, below the 50-day MA of 389.40, and below the 200-day MA of 456.38, indicating a bearish trend. The MACD of -7.33 indicates Positive momentum. The RSI at 46.27 is Neutral, neither overbought nor oversold. The STOCH value of 38.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4593.
Healios KK Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥17.03B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.20B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥49.55B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.31B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥19.06B | -11.30 | ― | ― | ― | 11.34% | |
43 Neutral | ¥154.90B | -35.18 | -253.07% | ― | ― | -12.69% |
* Healthcare Sector Average
JP:4593
Healios KK
367.00
93.00
33.94%
JP:4592
SanBio Co
1,985.00
-15.00
-0.75%
JP:4599
StemRIM Inc.
304.00
12.00
4.11%
JP:4978
ReproCELL Inc.
179.00
41.00
29.71%
JP:7774
Japan Tissue Engineering Co., Ltd.
596.00
151.00
33.93%
JP:7776
CellSeed Inc.
291.00
-252.00
-46.41%
Healios KK Corporate Events
Healios Signs ¥144 Million Stem Cell Supernatant Supply Deal With JENECELL
Apr 7, 2026
Healios K.K. has agreed to supply human bone marrow-derived somatic stem cell culture supernatant as a raw material for future cosmetics products to be marketed in South Korea by JENECELL, a South Korean subsidiary of Alfresa Corporation. The init...
Healios Wins ¥7 Billion METI Subsidy to Build Regenerative Medicine CDMO Hub in Kobe
Mar 27, 2026
Healios K.K., a leading Japanese regenerative medicine biotech, is expanding its cell and gene therapy capabilities across somatic stem cell and iPSC platforms, with late-stage clinical experience for its MAPC-based invimestrocel therapy and precl...
Healios to Restructure Capital to Eliminate Losses Without Diluting Shareholders
Feb 20, 2026
Healios K.K. plans to reduce portions of its capital stock and capital reserves and transfer these amounts to other capital surplus, before reallocating surplus to retained earnings to eliminate carry-forward losses and lower its tax burden. The t...
Healios Proposes New Board Slate Ahead of March Shareholders Meeting
Feb 20, 2026
Healios K.K. has nominated five candidates for its Board of Directors, including Chairman Hardy TS Kagimoto as director, current CFO Richard Kincaid as director, and three outside directors, Seigo Kashii, Yuko Yogo, and Glenn Gormley. The nominati...
Healios Issues FY2025 Results With Strong Caution on Forward-Looking Data
Feb 16, 2026
Healios K.K. released its FY2025 financial results materials primarily to disclose information to investors and other stakeholders, emphasizing that the data and analysis are provided for informational purposes only. The company underscores that t...
Healios Launches Japan Arm of Global Phase 3 Trial for ARDS Stem Cell Therapy
Feb 3, 2026
Healios K.K. has begun preparations to initiate patient enrollment in Japan for the global Phase 3 REVIVE-ARDS trial of its stem cell therapy HLCM051 (invimestrocel) in pneumonia-induced acute respiratory distress syndrome (ARDS), following comple...
Healios Deepens Alfresa Alliance for Stem Cell Culture Supernatant Distribution in Japan
Jan 21, 2026
Healios K.K. has signed a letter of intent with Japanese pharmaceutical wholesaler Alfresa Corporation to establish a framework for the continuous sale and purchase of its human bone marrow-derived somatic stem cell culture supernatant, HLSI071. B...
Healios Files Japan Trial Plan for Global Phase 3 ARDS Stem Cell Study
Jan 20, 2026
Healios K.K. has submitted a clinical trial plan notification to Japan’s Pharmaceuticals and Medical Devices Agency to begin domestic participation in the pivotal global Phase 3 REVIVE-ARDS study of its stem cell therapy HLCM051 (invimestroc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.